A genetic risk score⁣ can help predict which women‍ will develop invasive breast cancer after abnormal cells ‍have been found in their breast tissue, according to ⁤new research.

Researchers found that women with higher scores on a genetic blood test were twice as likely to develop breast cancer following a diagnosis of⁤ in situ carcinoma – a classification ⁣encompassing abnormal cells found in the breast ducts‍ (ductal carcinoma in situ) and milk-producing glands (lobular carcinoma ⁤in ⁢situ).

The findings, published in Cancer Epidemiology, Biomarkers⁢ & Prevention,⁢ suggest the⁢ score could help refine risk assessment and perhaps guide treatment decisions for⁣ women ⁣with these ⁢early-stage conditions.

Understanding In Situ Carcinoma

in situ carcinoma refers to abnormal cells that remain confined ⁢to their original location within the breast. It is not yet invasive, meaning the cells haven’t spread to surrounding tissues. Though, it does indicate an increased ‍risk of developing invasive cancer in the future. There are two main types:

• Ductal Carcinoma In situ (DCIS): Abnormal cells ⁤are found in the milk ducts.
• Lobular Carcinoma In ⁣Situ (LCIS): Abnormal cells are found in the lobules, the milk-producing glands. ⁤ The ⁢National Cancer‍ Institute ⁢notes that LCIS itself is not considered a true cancer, but a marker for increased risk.

Key Findings of the Study

The study revealed specific associations between the genetic risk score and cancer development:

• Women diagnosed with ductal carcinoma in situ⁢ (DCIS) with high genetic risk scores were ⁣twice as likely to develop cancer in their contralateral (other) ‍breast.
• Women diagnosed with ⁤lobular carcinoma in⁢ situ (LCIS)⁤ with high⁣ genetic⁢ risk scores were twice as⁤ likely to develop cancer in the‍ ipsilateral (same) breast.

This suggests the genetic risk score may help identify women with LCIS who are at higher risk of developing cancer in the same breast, potentially influencing surveillance strategies.

What Does This Mean for Patients?

Currently, management of in situ carcinoma varies. DCIS is frequently enough‍ treated ⁤with surgery ‍(lumpectomy or mastectomy) and radiation therapy. LCIS management often involves closer surveillance, as the risk of progression is lower. This new genetic risk score could potentially personalize these approaches.

“This research⁤ offers a promising⁣ tool for refining risk stratification among ⁣women diagnosed with in situ carcinomas,” says Dr. Jennifer Chen. “By identifying those at higher genetic ‍risk, we can potentially tailor surveillance schedules, consider preventative therapies, or ‍even‍ adjust surgical approaches to optimize outcomes.”